Icosavax (Nasdaq:ICVX) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ICVX Panoramica delle azioni

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology.

Informazioni sull'azienda

ICVX analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli azionisti sono stati diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Prezzo delle azioni volatile negli ultimi 3 mesi

Icosavax, Inc. Concorrenti

Scholar Rock Holding

NasdaqGS:SRRK

US$693.9m

Perspective Therapeutics

NYSEAM:CATX

US$824.6m

Vir Biotechnology

NasdaqGS:VIR

US$1.0b

REGENXBIO

NasdaqGS:RGNX

US$576.8m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Icosavax
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$15.31
Massimo di 52 settimane	US$16.11
Minimo di 52 settimane	US$4.75
Beta	1.28
1Variazione di 1 mese	-0.78%
Variazione a 3 mesi	50.84%
Variazione di 1 anno	68.80%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-56.22%

Notizie e aggiornamenti recenti

Recent updates

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29

Rendimenti per gli azionisti

	ICVX	US Biotechs	US Mercato
7D	-0.6%	-3.3%	1.9%
1Y	68.8%	18.7%	32.8%

Ritorno vs Industria: ICVX ha superato il US Biotechs che ha restituito 15.7 % nell'ultimo anno.

Rendimento vs Mercato: ICVX ha superato il mercato US che ha restituito 25.6 % nell'ultimo anno.

Volatilità dei prezzi

Is ICVX's price volatile compared to industry and market?
ICVX volatility
ICVX Average Weekly Movement	15.1%
Biotechs Industry Average Movement	10.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di ICVX è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 15% ) di ICVX è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2017	60	Adam Simpson	icosavax.com

Icosavax, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Icosavax con la sua capitalizzazione di mercato?
ICVX statistiche fondamentali
Capitalizzazione di mercato	US$777.79m
Guadagni(TTM)	-US$96.71m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-8.0x

Rapporto P/E

ICVX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ICVX Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$70.04m
Profitto lordo	-US$70.04m
Altre spese	US$26.67m
Guadagni	-US$96.71m

Ultimi guadagni dichiarati

Sep 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.90
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato ICVX nel lungo periodo?

Vedi performance storica e confronto

ICVX Panoramica delle azioni

Premi

Analisi del rischio

Icosavax, Inc. Concorrenti

NasdaqGS:SRRK

US$693.9m

NYSEAM:CATX

US$824.6m

NasdaqGS:VIR

US$1.0b

NasdaqGS:RGNX

US$576.8m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Recent updates

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Chief Medical Officer notifies of intention to sell stock

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target decreased by 12% to US$21.35

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

President notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target increased by 14% to US$23.51

Icosavax, Inc. Announces Positive Topline Interim Results from Its Phase 1 Clinical Trial of Ivx-A12 Against Respiratory Syncytial Virus (Rsv) and Human Metapneumovirus (hMPV) in Older Adults

Chief Scientific Officer notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 14% to US$20.69

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

President notifies of intention to sell stock

Icosavax, Inc. Appoints Jennifer Raymond as Senior Vice President, Technical Operations

President notifies of intention to sell stock

Chief Scientific Officer recently sold US$219k worth of stock

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.30 loss in 3Q 2021)

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax, Inc. Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Icosavax GAAP EPS of -$0.57

Chief Scientific Officer notifies of intention to sell stock

Icosavax Announces Results from Ivx-411 Drug Product Investigation and Outlines Additional Corporate Milestones

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Icosavax, Inc. Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

Icosavax, Inc.(NasdaqGS:ICVX) dropped from Russell 2000 Growth Index

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

High number of new directors

Icosavax, Inc., Annual General Meeting, Jun 10, 2022

Independent Chair recently bought US$300k worth of stock

Consensus revenue estimates increase by 36%

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Treasurer & Chief Business Officer notifies of intention to sell stock

Insider exercised options to buy US$1.2m worth of stock.

Chief Medical Officer exercised options to buy US$897k worth of stock.

President exercised options and sold US$91k worth of stock

High number of new and inexperienced directors

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Icosavax, Inc. Announces the Initiation of A Phase 1/1B Clinical Trial of IVX-121

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Icosavax, Inc. Riepilogo dei fondamenti

0.0x